by MM360 Staff | Jan 31, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Jan 31, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by Marisa Wexler, MS | Jan 30, 2026 | Myeloma News
A first-in-human clinical trial testing RMC-5127, an experimental treatment for people with pancreatic cancer and other cancers marked by a specific genetic mutation called RAS G12V, is now recruiting participants in the U.S. The Phase 1 trial (NCT07349537) is open to...
by MM360 Staff | Jan 30, 2026 | Publications
Trop Med Int Health. 2026 Jan 28. doi: 10.1111/tmi.70066. Online ahead of print. ABSTRACT BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) are reported to occur more frequently in Black populations, particularly African...
by Marisa Wexler, MS | Jan 29, 2026 | Myeloma News
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio. The data highlights a potential shift in managing a disease where “immune...
